IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 20, 2022

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2025

Conditions
Pleural Effusion, Malignant
Interventions
DRUG

IFN-γ and CIK cells, Tcm cells or CAR T cells

A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.

Trial Locations (1)

214000

RECRUITING

Affiliated Hospital of Jiangnan University, Wuxi

All Listed Sponsors
collaborator

Sichuan University

OTHER

collaborator

Zhejiang Provincial People's Hospital

OTHER

collaborator

Hunan Cancer Hospital

OTHER

collaborator

West China Hospital

OTHER

collaborator

Wuxi People's Hospital

OTHER

collaborator

Shenzhen Second People's Hospital

OTHER

lead

Affiliated Hospital of Jiangnan University

OTHER